Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, non-randomized, 1:1 parallel control and single dose
administration study design. Healthy subjects will be matched to moderate hepatic function
impaired (Child-Pugh B，7-9) subjects in age, gender and weight as parallel control, which
matches healthy with normal hepatic function according to the of subjects with impaired
hepatic function as, after enrollment of subjects with moderate impaired hepatic function
(Child-Pugh B，7-9). Hepatic function impaired group and control group both receive orally
single-dose of nemonoxacin malate capsule (0.5g). Collect the blood and urine samples before
and after the administration to perform pharmacokinetic analysis and safety observation.